Smruthi Organics Ltd

Smruthi Organic Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Smruthi Organics Ltd

₹ 114 -1.51%
19 May 4:01 p.m.
smruthiorganics.com BSE: 540686
About

Incorporated in 1989, Smruthi Organics Ltd
is a manufacturer of Active Pharmaceutical Ingredients[1]

Key Points

Business Overview:[1]
SOL is in the pharmaceutical business with presence in manufacturing bulk drugs and active pharmaceutical ingredients

Website BSE
  • Market Cap ₹ 130 Cr.
  • Current Price ₹ 114
  • High / Low ₹ 164 / 95.0
  • Stock P/E 34.8
  • Book Value ₹ 64.2
  • Dividend Yield 1.32 %
  • ROCE 7.99 %
  • ROE 5.17 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Debtor days have improved from 93.5 to 69.1 days.

Cons

  • The company has delivered a poor sales growth of -4.22% over past five years.
  • Company has a low return on equity of 5.14% over last 3 years.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
36.78 34.91 29.59 23.48 39.66 27.27 29.39 31.25 38.09 18.99 31.60 22.29 29.09
34.53 30.29 25.16 24.66 35.58 26.82 26.50 27.08 33.41 18.76 26.59 18.29 25.30
Operating Profit 2.25 4.62 4.43 -1.18 4.08 0.45 2.89 4.17 4.68 0.23 5.01 4.00 3.79
OPM % 6.12% 13.23% 14.97% -5.03% 10.29% 1.65% 9.83% 13.34% 12.29% 1.21% 15.85% 17.95% 13.03%
0.05 0.01 0.00 0.00 0.06 0.00 0.01 0.00 0.08 0.09 0.01 -0.44 0.01
Interest 0.25 0.33 0.39 0.32 0.37 0.41 0.44 0.51 0.52 0.46 0.66 0.25 0.31
Depreciation 1.24 1.24 1.38 1.45 1.59 1.29 1.33 1.37 1.50 1.41 1.51 1.67 1.75
Profit before tax 0.81 3.06 2.66 -2.95 2.18 -1.25 1.13 2.29 2.74 -1.55 2.85 1.64 1.74
Tax % 14.81% 25.49% 22.56% -22.03% 30.73% -26.40% 31.86% 35.37% 18.61% -29.03% 27.72% 14.63% 38.51%
0.69 2.29 2.07 -2.29 1.52 -0.92 0.78 1.48 2.23 -1.10 2.06 1.40 1.07
EPS in Rs 0.60 2.00 1.81 -2.00 1.33 -0.80 0.68 1.29 1.95 -0.96 1.80 1.22 0.93
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
77 74 79 97 137 131 126 133 141 128 126 102
72 63 69 94 121 116 98 115 131 116 114 89
Operating Profit 5 11 10 3 17 15 29 18 10 12 12 13
OPM % 6% 14% 13% 3% 12% 12% 23% 14% 7% 9% 10% 13%
0 0 1 0 1 4 1 1 0 0 0 -0
Interest 6 5 4 4 4 3 1 1 1 1 2 2
Depreciation 5 4 4 4 4 4 4 4 5 6 6 6
Profit before tax -6 2 3 -5 10 12 24 14 4 5 5 5
Tax % -33% 55% 39% -31% 30% 30% 29% 25% 8% 28% 27% 27%
-4 1 2 -3 7 8 17 10 4 4 4 3
EPS in Rs -3.34 0.63 1.39 -2.82 6.02 7.41 14.95 9.07 3.61 3.14 3.11 3.00
Dividend Payout % 0% 0% 0% 0% 11% 14% 20% 33% 55% 48% 48% 0%
Compounded Sales Growth
10 Years: 3%
5 Years: -4%
3 Years: -10%
TTM: -19%
Compounded Profit Growth
10 Years: 18%
5 Years: -26%
3 Years: -3%
TTM: 5%
Stock Price CAGR
10 Years: %
5 Years: -15%
3 Years: -10%
1 Year: -13%
Return on Equity
10 Years: 11%
5 Years: 7%
3 Years: 5%
Last Year: 5%

Balance Sheet

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 4 4 4 4 4 4 11 11 11 11 11 11
Reserves 26 27 28 25 33 39 49 56 57 58 60 62
45 37 33 31 28 16 10 3 6 12 17 8
34 35 20 25 37 30 21 18 32 37 23 22
Total Liabilities 109 103 85 85 101 88 92 88 106 118 112 104
35 32 30 30 30 32 31 33 37 40 45 47
CWIP 1 1 1 1 2 0 1 1 2 1 3 3
Investments 0 0 0 0 0 0 0 0 0 0 0 0
72 69 54 54 69 56 60 53 66 77 64 53
Total Assets 109 103 85 85 101 88 92 88 106 118 112 104

Cash Flows

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
9 14 9 5 12 21 23 2 12 4 10 22
-1 0 -0 -3 -4 -5 -3 7 -10 -7 -11 -9
-8 -14 -9 -2 -5 -17 -7 -12 -2 3 1 -12
Net Cash Flow -1 -0 0 0 2 -1 13 -3 0 -0 -0 1
Free Cash Flow 7 13 8 1 7 17 19 -4 3 -4 -2 14
CFO/OP 184% 128% 93% 159% 71% 160% 101% 33% 136% 46% 100% 182%

Ratios

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 103 95 97 95 97 68 62 78 96 117 94 69
Inventory Days 123 166 145 126 92 75 100 91 96 150 151 228
Days Payable 106 128 123 130 120 97 81 50 98 144 85 111
Cash Conversion Cycle 120 133 119 92 68 46 80 118 93 123 160 186
Working Capital Days 2 8 1 7 78 32 52 99 73 94 92 85
ROCE % 0% 9% 10% -1% 21% 25% 39% 21% 7% 8% 8% 8%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Expenditure as % of Turnover
%

Log in to view insights

Please log in to see hidden values.

Login
Number of Permanent Employees
Count
Diloxanide Furoate Sales Volume
KG
Metformin Capacity Utilization
%
Metformin HCL Installed Capacity
MT
Metformin HCL Sales Volume
KG
Telmisartan Sales Volume
KG
Total Annual Capacity
MT
Annual DMF/CEP Filings
Number
Total API Production Volume
KG
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
63.58% 63.58% 63.60% 63.84% 63.87% 63.87% 63.87% 64.73% 64.73% 64.73% 64.73% 64.73%
36.42% 36.43% 36.41% 36.16% 36.12% 36.13% 36.13% 35.27% 35.27% 35.28% 35.27% 35.27%
No. of Shareholders 5,1075,6055,7525,8775,8695,9725,9595,9056,0476,3566,1876,035

Documents

Announcements

Annual reports

Credit ratings